PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 112 filers reported holding PARATEK PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 3.09 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,088,000 | -7.5% | 112,143 | -2.7% | 0.00% | 0.0% |
| Q2 2018 | $1,176,000 | -32.3% | 115,282 | -13.8% | 0.00% | -50.0% |
| Q1 2018 | $1,738,000 | -27.4% | 133,682 | 0.0% | 0.00% | -33.3% |
| Q4 2017 | $2,393,000 | -28.7% | 133,682 | 0.0% | 0.00% | -25.0% |
| Q3 2017 | $3,355,000 | +4.1% | 133,682 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $3,222,000 | +6.7% | 133,682 | -14.8% | 0.00% | 0.0% |
| Q1 2017 | $3,020,000 | +25.0% | 156,858 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $2,416,000 | – | 156,858 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |